Skip to main content
Michael Curi, MD, Vascular Surgery, Newark, NJ

Michael A. Curi MD MPA


Chief, Vascular Surgery Rutgers-New Jersey Medical School

Join to View Full Profile
  • 90 Bergen StDivision of Vascular Surgery Suite 7100Newark, NJ 07103

  • Phone+1 973-972-9371

  • Fax+1 973-972-0092

Dr. Curi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Vascular Surgery - Independent, 2005 - 2006
  • University of Chicago
    University of ChicagoResidency, Surgery, 1998 - 2005
  • Rutgers New Jersey Medical School
    Rutgers New Jersey Medical SchoolClass of 1998

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2010 - 2025
  • FL State Medical License
    FL State Medical License 2018 - 2020
  • MD State Medical License
    MD State Medical License 2006 - 2010
  • IL State Medical License
    IL State Medical License 1998 - 2005
  • Vascular Surgery
    American Board of Surgery Vascular Surgery

Awards, Honors, & Recognition

  • Fellow American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Basilic Vein Superficialization Is an Effective Alternative to Transposition in Patients Requiring Brachiobasilic Arteriovenous Fistula  
    Joe T Huang, Frank T Padberg, Michael A Curi, Journal of Vascular Surgery

Authored Content

  • Basilic Vein Superficialization Is an Effective Alternative to Transposition in Patients Requiring Brachiobasilic Arteriovenous FistulaJuly 2018

Press Mentions

  • University Hospital Raises $400,000 for New State-of-Art Operating Room
    University Hospital Raises $400,000 for New State-of-Art Operating RoomOctober 24th, 2024
  • Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels
    Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular VesselsAugust 19th, 2021
  • Humacyte Launches Phase II Vascular Trauma Humacyl Vessel Trial
    Humacyte Launches Phase II Vascular Trauma Humacyl Vessel TrialOctober 26th, 2018
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: